ArticleNucleic acid therapeutics2021

Considerations of the Japanese Research Working Group for the ICH S6 & Related Issues Regarding Nonclinical Safety Assessments of Oligonucleotide Therapeutics: Comparison with Those of Biopharmaceuticals.

Yoko Hirabayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.